CABA-201 shows no CRS/ICANS/SAEs in first two patients; B cell depletion and disease score improvements observed

Cabaletta Bio, Inc.

First patient in IMNM cohort had creatinine kinase drop from 617 to 308 and TIS of 30 at week 12.
First SLE patient had SLEDAI-2K score drop from 26 to 10 at week 4.
Complete B cell depletion by day 15 post-infusion; immature naïve B cell repopulation seen at week 8 in IMNM patient.
All chronic maintenance therapies discontinued for both patients except planned prednisone taper for SLE patient.
18 sites open, 5 patients enrolled as of June 12, 2024; initial data support current dose of 1e6 cells/kg.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.